AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials. A ...

AstraZeneca AZN reported disappointing results from two late-stage studies that evaluated its investigational light chain ...

AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare ...

AstraZeneca on Wednesday said that its experimental therapy anselamimab did not meet the main goal of a late-stage study for ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...

AstraZeneca’s CARES phase III clinical programme of anselamimab in light chain amyloidosis fails to meet primary endpoint: Cambridge, UK Thursday, July 17, 2025, 09:00 Hrs [IST] ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...

The antibody anselamimab, which AstraZeneca picked up in its 2021 purchase of Caelum Biosciences, failed to improve survival and reduce hospitalizations, but the company sees promise in data from an ...

Research news of note last week included US biotech Crinetics Pharmaceuticals releasing new Phase III data on its acromegaly drug candidate Palsonify (paltusotine). AstraZeneca announced positive ...

The CARES clinical programme is the largest prospective investigation in cardiac AL amyloidosis to date with a total of 406 patients enrolled from 19 countries globally, including 281 patients with ...

AstraZeneca said its amyloidosis treatment anselamimab failed to reach its primary goal in a final-stage trial.